Healthcare | June 16, 2022
EPR-Technologies announces new approach to emergency care when CPR fails
EPR-Technologies is pursuing development of an unprecedented standard of emergency care when CPR fails
EPR-Technologies is pursuing development of an unprecedented standard of emergency care when CPR fails
The new subsidiary follows the recent announcement of Tetra's partnership with Cannvalate Pty Ltd for the performance of clinical trials of Tetra's drug candidates in Australia.
C2i Genomics expands its global reach and brings the first whole-genome sequencing minimal residual disease test to India
GSK to pay $2.1 billion upfront and up to $1.2 billion in potential development milestones
The abstract is about the cohort A, stage I of the ongoing global phase ? trial that evaluating the safety and efficacy of Catumaxomab in advanced GC patients with peritoneal metastasis
Data from the three studies formed the basis of the company's application for approval by regulatory agencies
The aim is to provide further insights into patients' lives in the effort to deliver better outcomes for people with psoriatic arthritis (PsA)
The European Commission granted CMA in December 2021 for use of Nuvaxovid in individuals aged 18 and over, and Novavax filed for expanded CMA for use in adolescents aged 12 through 17 in March 2022
First disclosure from PILOT study of Breyanzi in second-line large B-cell lymphoma underscores important role of cell therapy earlier in treatment paradigm
Leading this effort was Cytel’s principal research scientist and Professor of Health Research Methods at McMaster University in Canada, Dr. Edward Mills
Subscribe To Our Newsletter & Stay Updated
